NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $3.62 +0.01 (+0.14%) As of 03:42 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$3.47▼$3.6750-Day Range$3.09▼$4.7852-Week Range$2.77▼$6.70Volume15.91 million shsAverage Volume19.56 million shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$8.18Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms. Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience. Its pipeline has included internally discovered and developed drug candidates, as well as programs advanced through collaborations and strategic partnerships. The company’s approach combines laboratory experimentation with computational tools to support target discovery, compound design, preclinical testing and clinical development. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as an international biotechnology organization through its research activities, partnerships and collaborations. In 2024, Recursion completed a combination with Exscientia plc, a United Kingdom-based company specializing in artificial intelligence-driven drug design, expanding Recursion’s capabilities in computational chemistry and medicine discovery. Recursion was co-founded by Chris Gibson, who serves as chief executive officer.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRXRX MarketRank™: 2.737037528175 of 5 starsRecursion Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 448th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $8.18, representing about 126.3% upside from its current price of $3.62.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to remain at ($0.94) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted31.60% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 6.13.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 11.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.49 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest40 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows26 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 420% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $643,576.00 in company stock.Percentage Held by Insiders6.65% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesRecursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLCOctober 19 at 8:07 AM | americanbankingnews.comRecursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology MilestoneOctober 18 at 7:41 PM | finance.yahoo.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.October 20 at 1:00 AM | American Alternative (Ad)Recursion Pharmaceuticals, Inc. (RXRX) - What Are Researchers Saying About This Stock?October 18 at 3:48 AM | americanbankingnews.comMorgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)October 17 at 12:02 PM | theglobeandmail.comRecursion Pharmaceuticals (NASDAQ:RXRX) Upgraded to "Sell" at Wall Street ZenOctober 17 at 1:25 AM | americanbankingnews.comRXRX stock heads for its best day in over a year – what's driving the rally today?October 16, 2026 | msn.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 25,000 Shares of StockOctober 8, 2026 | insidertrades.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $4.09 at the beginning of the year. Since then, RXRX shares have decreased by 11.6% and is now trading at $3.6150. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced its earnings results on Wednesday, August, 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.01. The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 50.41% and a negative net margin of 945.94%. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $412 million in an initial public offering on Thursday, April 15th 2021. The company issued 24,242,424 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Top institutional investors of Recursion Pharmaceuticals include Green Alpha Advisors LLC (0.04%), TD Waterhouse Canada Inc. (0.01%), Whalen Wealth Management Inc. (0.01%) and Kieckhefer Group LLC (0.01%). Insiders that own company stock include Blake Borgeson, Najat Khan, Michael Secora, Ben R Taylor, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Robert Hershberg, Shafique Virani, Namandje Bumpus and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), SoundHound AI (SOUN), Tesla (TSLA), Micron Technology (MU) and IonQ (IONQ). Company Calendar Last Earnings8/05/2026Today10/20/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, RXRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees600Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$8.18 High Price Target$11.00 Low Price Target$5.90 Potential Upside/Downside+126.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.76 million Net Margins-945.94% Pretax Margin-954.29% Return on Equity-50.41% Return on Assets-38.25% Debt Debt-to-Equity Ratio0.01 Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual Sales$74.68 million Price / Sales25.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book1.69Miscellaneous Outstanding Shares535,340,000Free Float499,742,000Market Cap$1.94 billion OptionableOptionable Beta1.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RXRX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredI waited 13 years for this setupGold more than doubled after breaking a 13-year range in April 2024, then fell over 20 percent in its worst qu...Traders Agency | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
